Inotiv (NOTV) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Inotiv (NASDAQ: NOTV) is set to announce its Q3 2025 earnings on Wednesday, August 6th, with projections of a loss of ($0.15) per share and revenue of $127.05 million.
• The company's last reported earnings surpassed expectations, with a loss of ($0.18) per share against a forecast of ($0.24) and slightly more revenue than expected at $124.32 million.
• Following a recent decrease in price target from Lake Street Capital to $5.00, Inotiv's stock has shown a 6.7% increase, reaching $2.17 on Wednesday.

Inotiv (NASDAQ:NOTV - Get Free Report) is projected to announce its Q3 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $127.05 million for the quarter.

Inotiv (NASDAQ:NOTV - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The business had revenue of $124.32 million during the quarter, compared to analyst estimates of $123.97 million. Inotiv had a negative return on equity of 15.64% and a negative net margin of 18.21%. On average, analysts expect Inotiv to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Price Performance

Shares of Inotiv stock traded down $0.09 during trading on Friday, hitting $1.92. The stock had a trading volume of 312,220 shares, compared to its average volume of 393,321. The company has a debt-to-equity ratio of 2.49, a current ratio of 1.50 and a quick ratio of 1.18. The firm has a market cap of $65.95 million, a P/E ratio of -0.60 and a beta of 3.99. The business has a fifty day moving average of $2.20 and a two-hundred day moving average of $2.65. Inotiv has a fifty-two week low of $1.15 and a fifty-two week high of $6.48.

Analyst Ratings Changes

Separately, Lake Street Capital cut their price objective on Inotiv from $6.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, May 8th.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.